Andrew Cheek, MD
Ophthalmology · Spokane, WANPI 1790979383
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by US Retina LLC at 43.0% of the total. Reporting peaked in 2019 at $360 and has fallen 51.0% since, to $176 in 2025.
Across 26 payments — averaging $59.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$667
- Apellis Pharmaceuticals, Inc.$209
- AbbVie$171
- Genentech USA, Inc.$169
- Genentech, Inc.$154
- Regeneron Healthcare Solutions, Inc.$124
- plus $55 from 1 others
Across 31 payments — averaging $6582.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$114K
- Janssen Research & Development, LLC$50K
- Roche TCRC, Inc.$40K
What the payments were for
- Food & beverage$88357%
- Ownership interest$66743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $667 |
| Apellis Pharmaceuticals, Inc. | 5 | $209 |
| AbbVie(2 entities) | 4 | $171 |
| Genentech USA, Inc. | 5 | $169 |
| Genentech, Inc. | 1 | $154 |
| Regeneron Healthcare Solutions, Inc. | 4 | $124 |
| Eyepoint US, Inc. | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$154
- Syfovre$125
- OZURDEX$125
- VUITY$125
How this compares
$1,549 in reported general payments places this provider in the 65th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 134 | $5,933 |
| Atropine Sulfate | 72 | $2,335 |
| Bromfenac Sodium | 17 | $1,930 |
| Ofloxacin | 81 | $927 |
| Latanoprost | 30 | $307 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $285 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Spokane
- Barbara SmitSpokane$110K
- Robert WirthlinSpokane$64K
- Jessica WeinsteinSpokane$9K
- Gary FillmoreSpokane$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.